MOESM6 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsA Riccio, Giorgio Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0
MOESM3 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsA Riccio, Giorgio Walter Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0
MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsAnna Riccio, Giorgio Walter Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0
MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsAnna Riccio, Giorgio Walter Canonica, Dario Di Silvestre et al.|Figshare|2017Cited by 0
MOESM6 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsA Riccio, Giorgio Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0